LIB Therapeutics

LIB Therapeutics Announce Positive Results from Lerodalcibep 72-Week Open-Label Extension Studies at American Heart Association 2024. The results from two studies in over 1,000 patients treated with Lerodalcibep for more than 2 years with no signs of LDL-C attenuation and good tolerability, provide further reassurance of the ability of Lerodalcibep to provide long-term LDL-C control. https://lnkd.in/g_DeGac7 #PCSK9 #lerodalcibep #LDLC #cholesterol #CVD

1 in 5 heart attacks under the age of 45 are due to familial hypercholesterolemia. Get checked today.

Celebrating National Cholesterol Education Month this September. Make sure you know your cholesterol levels – and take steps to prevent or reduce high cholesterol. LIB Therapeutics is developing, Lerodalcibep, a once-monthly, PCSK9 lipid lowering therapy that has demonstrated in clinical trials to lower LDL-C levels by 59-77% on top of statins. #PCSK9 #lerodalcibep #LIB #cholesterol

From American Society for Preventive Cardiology (ASPC): "Cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk." https://bit.ly/4cHOwK4 Lower LDL-C for Longer is Better. #lerodalcibep #LIB #PCSK9

“Many individuals with Familial hypercholesteremia (FH) do not know that they're walking around with a risk of early onset heart disease. Maybe as few as 10% actually have been diagnosed properly. There are many reasons for that, but the biggest reason is that people are not looking for it...” -- Dr. Joshua Knowles Familial hypercholesteremia (FH) affects 1 in every 220 people across all ages and ethnic backgrounds. As you’ll hear in this American Heart Association podcast, that’s at least 1.3 million Americans and as few as 10% have been properly diagnosed. https://bit.ly/4f87bkA

Phase 3 LIBerate HR (high risk) study achieved co-primary endpoint with Lerodalcibep demonstrating significant and persistent LDL-C reductions over 52 weeks of 56% (60.6 mg/dL) at Week 52 and 62% (74.5 mg/dL) at mean of Weeks 50 and 52. In addition, over 90% of all patients achieved the new more stringent ESC targets during the study of ≥ 50% reduction in LDL-C from baseline and recommended LDL-C targets of < 55 mg/dL with CVD or very high risk or < 70 mg/dL if at high risk. Lerodalcibep, a novel, potent, small binding protein, third-generation PCSK9 inhibitor, has been developed as a more convenient, once-monthly dose in a small injection volume and with long-ambient stability. #LIBerate #Lerodalcibep #PCSK9

Positive Results from Phase 3 LIBerate-HR (High Risk CVD) Study Announced at American College of Cardiology 2024 #lerodalcibep #PCSK9 #CVD #LDL https://lnkd.in/gWBX-6Qu

LIB Therapeutics to participate in Piper Sandler Virtual Cardio Day focused on highlights from ACC 2024 Conference on April 10, 2024. https://lnkd.in/gZhCzRGt

We'll be presenting new data from our Phase 3 LIBerate 004 study at the American College of Cardiology 2024 (#ACC24). The results demonstrate Lerodalcibep’s long-term impact on LDL-C, a robust predictor of future cardiovascular risk events, in patients with heterozygous familial hypercholesterolemia on background stable lipid-lowering therapy. https://lnkd.in/gNHk_fkx

We'll be presenting topline data from our registration-enabling Phase 3 LIBerate 006 study at the American College of Cardiology 2024 (#ACC24). The results demonstrate Lerodalcibep's impact on LDL-C, a robust predictor of future cardiovascular risk events, in patients with, or at very-high or high risk, for cardiovascular disease on stable lipid-lowering therapy. https://lnkd.in/gNHk_fkx